From Research findings to Therapeutic opportunity:
The study presented here suggests that Luteolin, by increasing the expression of its target genes, it may: (i) increase the expression of CADM1; (ii) decreases BMI1 translocation; (iii) increases tumor suppressor INK4a/p16 expression; and (iv) restores chemosensitivity in drug-resistant Human cancers (Fig 1.).
Thereby, it may inhibit proliferation, chemoresistance and apoptosis of cancer cells. Thus, pharmacological formulations encompassing “Luteolin or its analogues or Luteolin in combination with any of known anti-cancer drugs” (figs. 2, 3) may be used to inhibit cancer progression.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Undisclosed information: How Luteolin increases the expression of CADM1, and INK4a/p16?
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at firstname.lastname@example.org
Citation: Boominathan, L., Natural product-derived therapy for overcoming chemoresistance in Human cancers:Luteolin, a flavonoid found in Salvia tomentosa, Perilla, and thyme among others, increases the expression of CADM1, decreases BMI1 translocation, increases tumor suppressor INK4a/p16 expression and restores chemosensitivity in drug-resistant Human cancers via down regulation of its target gene, 13/December/2016, 10.08 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com